SEC Form 4 · accession 0001104659-15-049012

CATABASIS PHARMACEUTICALS INC · CATB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jun 30, 2015

Accepted (ET)

Jun 30, 2015 · 6:45 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001454789

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Jun 30, 2015	C	1,079,115	—	A	1,079,115	D
Common Stock^F1,F2	Jun 30, 2015	C	330,098	—	A	1,409,213	D
Common Stock^F2	Jun 30, 2015	P	223,439	$12.00	A	1,632,652	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F2,F1	—	Jun 30, 2015	C	13,866,666	D	—	—	Common Stock	1,079,115	0	D
Series B Preferred Stock^F2,F1	—	Jun 30, 2015	C	4,241,780	D	—	—	Common Stock	330,098	0	D

F1The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2These shares are owned directly by MedImmune Ventures, Inc. Ron Laufer is the Senior Managing Partner of MedImmune Ventures, Inc., and as a result, Dr. Laufer may be deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures, Inc. Dr. Laufer disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.